Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rolinsatamab talirine
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Rolinsatamab talirine (ABBV-176) is an antibody-drug conjugate (ADC) developed by AbbVie for the treatment of advanced solid tumors. It consists of a humanized monoclonal antibody (h16f/PR-1594804) targeting the prolactin receptor (PRLR), which is overexpressed in several solid tumor types. The antibody is conjugated to a highly potent DNA cross-linking pyrrolobenzodiazepine dimer cytotoxin (PBD; SGD-1882). The mechanism of action involves binding to PRLR on tumor cells and delivering the PBD payload intracellularly, resulting in DNA crosslinking and cell death. Preclinical studies showed activity against breast cancer models including triple-negative and low PRLR-expressing tumors. Clinical development included a phase 1 trial in patients with advanced solid tumors likely to express PRLR; however, this study was terminated due to significant toxicities such as cytopenias and cumulative effusions/edema[1][2][6].
- Brand names
- rolinsatamab talirine
- Other names
- ABBV-176ABBV176ABBV 176h16f (PR-1594804)
02
Targets
PRLR (Prolactin receptor)
Beyond the preview
Go deeper on rolinsatamab talirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rolinsatamab talirine.